Neuralink Projects $1 Billion Annual Revenue by 2031, Targets 20,000 Brain Implants per Year

Elon Musk’s brain-interface company, Neuralink Corp., is projecting over $1 billion in annual revenue by 2031 through the implantation of its advanced brain chips in 20,000 individuals each year. According to internal documents reviewed by Bloomberg, this ambitious growth forecast highlights Musk’s expansive vision for the future of neurotechnology and human-computer integration.

Neuralink, which began its first human trials last year, has implanted chips in fewer than 10 individuals to date. However, the company anticipates receiving U.S. regulatory approval for its first commercial product, the Telepathy chip, by 2029. This device is designed to enable users to control external devices using only their thoughts—potentially revolutionizing assistive technologies for people with mobility challenges.

By 2030, Neuralink plans to operate five large-scale clinics and offer three specialized brain chips: Telepathy for device control, Blindsight to restore vision to the blind, and Deep, which targets neurological disorders such as Parkinson’s disease. The company projects performing 10,000 surgeries annually by 2030, generating over $500 million in revenue—based on an estimated reimbursement rate of $50,000 per procedure.

Despite its promising roadmap, Neuralink faces major regulatory obstacles. The U.S. Food and Drug Administration (FDA) has not yet approved any permanent brain-computer interface (BCI) for humans. Nonetheless, early trials have shown promising results: paralyzed patients using Neuralink implants have successfully controlled computers, played video games, and edited video content with their minds. Vision-restoring technology is also undergoing tests in primates.

Founded in 2017, Neuralink has raised $1.3 billion in funding and is valued at $9 billion. In April, the company launched a global volunteer recruitment campaign for its ongoing research. While the field of neurotechnology continues to expand, experts remain cautious, citing Elon Musk’s history of optimistic timelines, such as previous predictions for Tesla’s self-driving capabilities. Neuralink’s path forward hinges on proving long-term safety and efficacy in one of the most complex and sensitive areas of medical science.

Source: Nairametrics